Sentences with phrase «federal financial aid programs including»

Department of Education Federal government agency that is responsible for federal financial aid programs including Pell Grants, Perkins Loans, Stafford Loans, parents» PLUS loans, and the Work - Study program.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

According to the Higher Education Act (HEA) of 1965, all institutions receiving Title IV funds must submit specific data about their educational programs, student population, enrollment, attrition, and completion rates, staff and faculty, financial information, tuition and fees, and allocation of all student financial aid (NCES, n.d.) IPEDS HistoryIn 1995, NCES established the National Postsecondary Education Cooperative (NPEC) as a «voluntary organization that encompasses all sectors of the postsecondary education community including federal agencies, postsecondary institutions, associations, and other organizations interested in postsecondary education data collection» (NPEC, n.d., p. 4).

The Trump - DeVos budget and the House Appropriation Committee bill raid student aid programs — including the federal Pell Grant reserve, which the federal government slowly established after an inadequate rainy day fund led to painful cuts56 to the program — by $ 3.9 billion and $ 3.3 billion, respectively.57 The Pell Grant is the fundamental building block of financial aid support for low - income students.

-- The National Association of Student Financial Aid Administrators is recommending changes to the Federal Work - Study program that include revising the campus - based aid allocation formula and expanding the definition of the community service requirement: http://politico.pro/28WptAid Administrators is recommending changes to the Federal Work - Study program that include revising the campus - based aid allocation formula and expanding the definition of the community service requirement: http://politico.pro/28Wptaid allocation formula and expanding the definition of the community service requirement: http://politico.pro/28Wpt5Z.

The Department of Education's responsibilities include gathering data to assess how well certain programs and grants are working, awards Pell grants federal financial aid through loans and provides oversight over state policies to prevent discrimination.

The routine uses of this information include, but are not limited to, its disclosure to federal, state, or local agencies, to private parties such as relatives, present and former employers, business and personal associates, to consumer reporting agencies, to financial and educational institutions, and to guaranty agencies in order to verify your identity, to determine your eligibility to receive a loan or a benefit on a loan, to permit the servicing or collection of your loan (s), to enforce the terms of the loan (s), to investigate possible fraud and to verify compliance with federal student financial aid program regulations, or to locate you if you become delinquent in your loan payments or if you default.

US Department of Education (ED or USED) Government agency that administers several federal student financial aid programs, including the Federal Pell Grant, the Federal Work - Study Program, the Federal Perkins Loans, the Federal Stafford Loans and the Federal PLUSfederal student financial aid programs, including the Federal Pell Grant, the Federal Work - Study Program, the Federal Perkins Loans, the Federal Stafford Loans and the Federal PLUSFederal Pell Grant, the Federal Work - Study Program, the Federal Perkins Loans, the Federal Stafford Loans and the Federal PLUSFederal Work - Study Program, the Federal Perkins Loans, the Federal Stafford Loans and the Federal PLUSFederal Perkins Loans, the Federal Stafford Loans and the Federal PLUSFederal Stafford Loans and the Federal PLUSFederal PLUS Loans.

Other provisions on this progressive policy include reduced student loan interest rates by half, federal refinancing eligibility, simplified financial aid application process, and expansion of the federal work - study program.

These infobases include compilations of current law, regulations, regulation interpretations, accounting and recordkeeping procedures and Act amendments which affect federal student financial aid programs.

Eligible higher education institutions include all accredited post-secondary institutions that are eligible to participate in federal financial aid programs.

By submitting the FAFSA, students are able to apply for a variety of financial aid programs, including federal grants and student loans.

It is free to file the FAFSA and the majority of students may qualify for some type of financial aid, including pell grants, work - study programs, and federal loans.

Qualified expenses include tuition and fees; required books, supplies, and equipment; computers, peripheral equipment, educational software, and internet service; and certain room and board costs at any university, college, or technical school in the United States or abroad that participates in federal student financial aid programs.

Other sources for financial aid include federal and private loans; education investment accounts; prepaid tuition plans; and military service programs.

In compliance with Title IX of the Education Amendments of 1972, Title VI and VII of the Civil Rights Act of 1964, and Section 504 of the Rehabilitation Act of 1973, the Americans with Disabilities Act, as amended, the Age Discrimination Act of 1975 and applicable federal, state, and local laws, and our institutional values, The Cooper Union does not discriminate on the basis of race, color, religion, sex, sexual orientation, gender identity or expression, age, disability, national or ethnic origin, military status, marital status, partnership status, familial status or any other legally protected characteristic, in admissions, financial aid, or employment practices, or in the administration of any Cooper Union educational program or activity, including athletics.

We participate in both the Federal Student Aid Programs and Illinois State MAP Program, along with other miscellaneous financial aid programs from various sources (including Veterans ProgramAid Programs and Illinois State MAP Program, along with other miscellaneous financial aid programs from various sources (including Veterans PrPrograms and Illinois State MAP Program, along with other miscellaneous financial aid programs from various sources (including Veterans Programaid programs from various sources (including Veterans Prprograms from various sources (including Veterans ProgramsPrograms).

Services may include child care and relocation help as well as financial support from programs federal and state aid programs.